Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.
在上消化道內視鏡檢查前使用胰高血糖素樣肽-1受體激動劑與肺部吸入風險或程序中止的關聯：隊列研究。
BMJ 2024-10-22
Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
葡萄糖樣肽受體1激動劑治療與空腹接受麻醉下內視鏡檢查患者胃內容物存在的關聯：一項歷史性的世代研究。
Can J Anaesth 2024-03-15
Clinical Outcomes and Safety of Upper Endoscopy While on Glucagon-Like Peptide-1 Receptor Agonists.
接受胰高血糖素樣肽-1受體激動劑治療時進行上消化道內視鏡檢查的臨床結果和安全性。
Clin Gastroenterol Hepatol 2024-05-01
Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes.
糖尿病患者上消化道內視鏡檢查時，GLP-1 受體激動劑不會增加誤吸的風險。
Clin Gastroenterol Hepatol 2024-05-17
Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.
在內視鏡程序前是否有必要停止使用胰高血糖素樣肽-1受體激動劑？一項回顧性研究。
World J Gastroenterol 2024-08-01
Risk of Aspiration Pneumonitis After Elective Esophagogastroduodenoscopy in Patients on Glucagon-Like Peptide-1 Receptor Agonists.
使用 Glucagon-Like Peptide-1 受體激動劑的患者在選擇性食道胃十二指腸鏡檢查後吸入性肺炎的風險。
Cureus 2024-09-06
Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.
GLP-1 受體激動劑對門診患者內視鏡結果的實際影響：大型三級醫療中心的回顧性研究。
J Clin Med 2024-09-28